GlassScriptPhysician profile
Charles B Arber
NPI 1831758945
$3,924.27
in general payments reported to CMS, 2019-2025
23 companies · $1,607 in 2025
The $1,607 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $56.85 · 2023: $1,154 · 2024: $1,107 · 2025: $1,607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,867.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $761.54 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $589.22 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $516.40 | 2022-2025 | Trelegy Ellipta, Shingrix |
| Abbvie INC. | $507.83 | 2023-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $452.01 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $174.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $172.04 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Corcept Therapeutics | $145.73 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $121.63 | 2024-2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $120.29 | 2022-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $89.88 | 2022-2025 | |
| Viatris Specialty LLC | $45.02 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.45 | 2024 | Jardiance |
| Vanda Pharmaceuticals INC. | $30.64 | 2025 | Hetlioz, Fanapt |
| Phathom Pharmaceuticals, INC. | $29.88 | 2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $23.90 | 2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.55 | 2025 | Caplyta |
| Mannkind Corporation | $17.36 | 2023 | Afrezza |
| Merck Sharp & Dohme LLC | $17.00 | 2023 | Belsomra |
| Sumitomo Pharma America, INC. | $17.00 | 2025 | Gemtesa |
| Evofem Biosciences, INC. | $14.72 | 2023 | Phexxi |
| Cequr Corporation | $14.51 | 2023 | Cequr Simplicity |
| Pfizer INC. | $14.39 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Arber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.